Navigation Links
BioCryst Pharmaceuticals to Announce Fourth Quarter and Year End 2008 Financial Results on February 6, 2009
Date:1/30/2009

BIRMINGHAM, Ala., Jan. 30 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) today announced that its fourth quarter and fiscal year 2008 financial results will be released on Friday, February 6, 2009. Following the release, BioCryst will host a conference call and Web cast at 8:30 a.m. Eastern Time to discuss the financial results and provide an update on the Company's programs. The call will be led by Jon P. Stonehouse, President and Chief Executive Officer, Stuart Grant, Chief Financial Officer and Dr. William P. Sheridan, Chief Medical Officer.

The Web cast can be accessed by logging onto http://www.biocryst.com. Please connect to the Web site at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed. To participate in the conference call, please dial 1-800-860-2442 (United States) or 1-412-858-4600 (International). No passcode is needed for the call. The audio portion of the Web cast will be archived and available for replay for 14 days.

About BioCryst

BioCryst is an integrated biopharmaceutical company utilizing crystallography and structure-based drug design to develop a deep pipeline of novel therapeutics targeting major illnesses. BioCryst is currently advancing investigational new drugs discovered in-house in late-stage clinical trials for influenza and lymphoma. In addition, the Company has a pre-clinical portfolio of novel compounds, directed against infectious, cardiovascular, and autoimmune disease targets, to create long-term sustainable value. The Company's strategic alliances with the U.S. Department of Health and Human Services, Shionogi & Co., Ltd., Green Cross Corporation and Mundipharma International Holdings Ltd. validate its scientific foundation and the utility of
'/>"/>

SOURCE BioCryst Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. BioCryst to Release Third Quarter 2007 Financial Results on Thursday, November 8, 2007
2. BioCryst Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 8, 2008
3. BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
4. BioCryst to Present at the Rodman and Renshaw 10th Annual Healthcare Conference
5. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
10. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Pasierb, President ,, NEW YORK, Dec. 14 ... the Future study (MTF) -- the largest survey on ... 12th graders -- underscores that teens, intentional abuse of ... a cause for concern, with an alarming number of ... relatives. ,, Teen Abuse of Medication ...
(Date:12/14/2009)... SANTA ANA, Calif., Dec. 14 Grubb & Ellis ... directors has authorized a daily distribution to stockholders of record ... the period commencing on Jan. 1, 2010 and ending on ... on 365 days in the calendar year and will be ... a purchase price of $10.00 per share. These distributions ...
(Date:12/14/2009)... 14 On December 9, 2009, the United ... government,s position that private insurance companies are "plans" and ... Although other federal courts have held that contracts issued ... under Title 18 Section 1347, US vs. Frost ... has been held to be a "plan," because, as ...
(Date:12/14/2009)... had been treated, hadn,t spread, study finds , , MONDAY, ... the risk of death in male colon cancer survivors, ... 1986, included 668 men who,d been treated for stage ... had not spread (nonmetastatic cancer). Every two years, the ... new cancer and disease diagnoses, as well as their ...
(Date:12/14/2009)... is small and shouldn,t worry most users, researcher says ... who take antidepressants may have a small but statistically ... women not on the medications, a new study finds. ... significance," stressed Dr. Jordan W. Smoller, an associate professor ... of a report in the Dec. 14 issue of ...
Breaking Medicine News(10 mins):Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 2Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 3Health News:Grubb & Ellis Healthcare REIT II Declares Initial Distribution 2Health News:Grubb & Ellis Healthcare REIT II Declares Initial Distribution 3Health News:Insurance Now Subject to Federal Jurisdiction 2Health News:Physical Activity May Prolong Survival After Colon Cancer 2Health News:Antidepressants May Raise Women's Stroke Risk 2Health News:Antidepressants May Raise Women's Stroke Risk 3
... Hydra Booster Concentrated Conditioner Fortifies Water with Naturally Occurring Electromagnetic ... Balance , ... Los Angeles, CA ... a sea of bottled water, sports drinks, energy beverages and ...
... AMN Healthcare announced today that,it has been ... Organizations and continues to earn the Commission,s Gold ... now includes its,allied division: Med Travelers., AMN ... to be certified under,the Joint Commission,s corporate certification, ...
... The dog days of summer are here, and,for ... -- allergies. With an,estimated 40 percent of children and ... the rise. Americans are spending three billion,dollars a year ... their symptoms. Doctors say in-vitro blood tests, the,latest generation ...
... Anxiety is a normal human response to stress, but ... of excessive and irrational fears, such as obsessive-compulsive disorder, ... are available and can involve either behavioral therapy or ... these two treatments would result in even better results," ...
... Health, a,leading national provider of individual medical, ... that Jennifer Kopps-Wagner has been,named Senior Vice ... Kopps-Wagner joined Assurant Health in 1999, holding ... department. In her most recent role as,Vice ...
... Enhance Patient Safety and,Reduce Healthcare Costs, BETHESDA, ... nation,s first and only nationwide data collection program ... for a fall,2008 launch of its pilot. The ... donations, including an $84,000 contribution by Fenwal Inc., ...
Other Medicine News:Health News:Hydra Booster Energizes Ordinary Drinking Water for Better Absorption and Optimum Hydration, Stopping Symptoms of 'Hidden' Dehydration 2Health News:Hydra Booster Energizes Ordinary Drinking Water for Better Absorption and Optimum Hydration, Stopping Symptoms of 'Hidden' Dehydration 3Health News:Hydra Booster Energizes Ordinary Drinking Water for Better Absorption and Optimum Hydration, Stopping Symptoms of 'Hidden' Dehydration 4Health News:Hydra Booster Energizes Ordinary Drinking Water for Better Absorption and Optimum Hydration, Stopping Symptoms of 'Hidden' Dehydration 5Health News:AMN Healthcare Announces Joint Commission Re-Certification 2Health News:D-cycloserine may improve behavioral therapy treatment for anxiety 2Health News:Assurant Health Names Jennifer Kopps-Wagner Senior Vice President and General Counsel 2Health News:First Ever National Biovigilance Network in the U.S. Reaches $1 Million in Funding, Prepares for Fall Pilot Launch 2Health News:First Ever National Biovigilance Network in the U.S. Reaches $1 Million in Funding, Prepares for Fall Pilot Launch 3Health News:First Ever National Biovigilance Network in the U.S. Reaches $1 Million in Funding, Prepares for Fall Pilot Launch 4Health News:First Ever National Biovigilance Network in the U.S. Reaches $1 Million in Funding, Prepares for Fall Pilot Launch 5
(Date:12/14/2009)... directors of Eli Lilly and Company (NYSE: ... quarter of 2010 of $0.49 a share on outstanding ... March 10, 2010 to shareholders of record at the ... ,, Lilly, a leading innovation-driven corporation, is developing a ... research from its own worldwide laboratories and from collaborations ...
(Date:12/14/2009)... -- Cardinal Health today announced that executives of the ... Goldman Sachs CEO Unplugged Conference on ... Conference Center in New York. 28th Annual ... Noon EST at the Westin St. Francis Hotel in ... will discuss Cardinal Health,s diverse products and services, company ...
(Date:12/14/2009)... Conn., Dec. 14 Zargis Medical Corp., ... SPDE ) and a spin-off from Siemens Corporate ... that it has begun selling its award-winning Zargis ... ,, Cardioscan and its accompanying Bluetooth®-enabled electronic stethoscope ... "2009 Innovation of the Year." ...
Breaking Medicine Technology:Cardinal Health Executives to Speak at Two Investor Events in January 2Zargis Cardioscan 'The Intelligent Stethoscope' Now Available on Amazon.com 2Sheller P C Law Firm Instrumental in Pfizers 242 3 Billion Settlement Today in Largest Pharmaceutical Whistleblower Case in History 56021 1Sheller P C Law Firm Instrumental in Pfizers 242 3 Billion Settlement Today in Largest Pharmaceutical Whistleblower Case in History 56021 2Sheller P C Law Firm Instrumental in Pfizers 242 3 Billion Settlement Today in Largest Pharmaceutical Whistleblower Case in History 56021 3Sheller P C Law Firm Instrumental in Pfizers 242 3 Billion Settlement Today in Largest Pharmaceutical Whistleblower Case in History 56021 4Sheller P C Law Firm Instrumental in Pfizers 242 3 Billion Settlement Today in Largest Pharmaceutical Whistleblower Case in History 56021 5eDiets com Selects Karlin+Pimsler to Lead Creative Turnaround 56017 1eDiets com Selects Karlin+Pimsler to Lead Creative Turnaround 56017 2MDS Announces Voting Support Agreements 56014 1MDS Announces Voting Support Agreements 56014 2MDS Announces Voting Support Agreements 56014 3
Swing-Arm™ Scatter Shield® provides lower extremity protection for personnel close to the tube. 24"Wx32"L lead shield swings 180 along table. Ideal for cardiac cath, special studies, electr...
Ball-and-socket center mount can rotate 360, allowing them to be turned hoirzontally, vertically, or at any angle. Very versatile! Available with or without torso placement contour cutout and in thre...
... Primarily designed to prevent lower body exposure ... used on any table where X-ray fluoroscopy is ... protection in applications where C-arm fluoroscopy units are ... are offered, each equipped with a 17 cm ...
Economy Apron, Excellent Protection, Value Priced...
Medicine Products: